New Data Spark Debate on Cost and Value of Breakthrough Cholesterol Meds

A new analysis calls for drastic price reductions for PCSK9 inhibitors, breakthrough lipid-lowering medications. Data published in the Journal of the American Medical Association suggest that the treatments would need to be reduced to two-thirds their current price to meet analysts’ cost-effectiveness thresholds.

But critics say the analysis drastically overestimates the number of patients who receive the treatment – and overlooks the individual value of these treatments for patients whose high cholesterol is not adequately controlled by traditional statins.

More at Institute for Patient Access